Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia: Patient considerations

Lesia V. Tchobaniouk, Erin E. McAllister, Danielle L. Bishop, Rachel M. Carpentier, Katharine R. Heins, Robert J. Haight, Jeffrey R. Bishop

Research output: Contribution to journalArticle


Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral for-mulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risper-idone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.

Original languageEnglish (US)
Pages (from-to)2233-2241
Number of pages9
JournalPatient Preference and Adherence
StatePublished - Jan 1 2019


  • Adherence
  • Antipsychotic medications
  • Long-acting injections
  • RBP-7000
  • Risperidone

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint Dive into the research topics of 'Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia: Patient considerations'. Together they form a unique fingerprint.

  • Cite this